Dear Sir, Please find attached audited financial results for the year ended March 31, 2026.
PGHL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Procter & Gamble Health Ltd reported audited financial results for FY26 ended March 31, 2026. Revenue from operations grew to ₹1,40,797 lakhs compared to ₹93,417 lakhs in the prior 9-month period (July 2024 – March 2025). Net Profit after tax stood at ₹32,691 lakhs versus ₹23,441 lakhs in the comparable prior period. The company declared a final dividend of ₹45 per equity share, bringing total dividend for the year to ₹205 per share (including interim and special dividends). The statutory auditors Haribhakti & Co. LLP issued an unmodified opinion on the financial statements. Note: The company changed its financial year-end from June 30 to March 31, making the previous period only 9 months versus the current 12-month period, affecting comparability. On a sequential Q4 basis, revenue grew ~19% YoY and PAT grew ~55% YoY.
Strong full-year results with revenue and profit growth; clean audit with unmodified opinion; heavy dividend payout of ₹205 per share signals confidence but reduces retained earnings. The stock appears to be in a growth phase with improving bottom line.